Analytical Data
-
基因名
JAM-A/CD321
- Application
-
别名
CD321; F11R; KAT; JAM-A; JAMA; JCAM; PAM1; Coagulation Factor XI Receptor; Platelet F11 receptor; Platelet adhesion molecule 1
-
种属
Rat
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9JHY1
-
表达区间
Lys27~Gly238
-
分子量
30kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
JAM-A (Junctional Adhesion Molecule A), also known as CD321, is a cell adhesion molecule predominantly expressed in endothelial cells and immune cells. It plays a crucial role in maintaining the integrity of tight junctions in epithelial and endothelial barriers, regulating leukocyte transmigration, and contributing to various physiological and pathological processes, including inflammation, tumor metastasis, and tissue regeneration. The research surrounding JAM-A/CD321 has gained increasing interest due to its involvement in various diseases, such as cancer, autoimmune disorders, and cardiovascular diseases, where it can influence cell signaling and adhesion mechanisms. Additionally, the functional diversity of JAM-A is highlighted by its interactions with multiple binding partners, including integrins and other adhesion molecules, which modulate cell behavior and fate. The development of recombinant JAM-A proteins facilitates detailed studies of its structure-function relationship, underlying molecular mechanisms, and potential therapeutic applications. Understanding the biological roles of JAM-A/CD321 through recombinant protein studies may offer insights into novel therapeutic strategies targeting inflammatory and metastatic pathways, highlighting its significance in biomedical research and potential clinical interventions.
